In the inverse-variance-weighted model, genetically proxied inhibition of HMG-CoA reductase equivalent to a 1 mmol/L decrement in LDL cholesterol levels by the HMGCR score was associated with a decreased risk of ankylosing spondylitis (OR, 0.57; 95% CI, 0.38–0.85; P value = 5.7×10–3) (Figure 1). Here, HMGCR is linked to ankylosing spondylitis.